Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Benitec Biopharma Inc.NASDAQ: BNTC
Total Assets · Q3 FY2026 · quarter ended Mar 2026
Total assets rises 77.7% from a year ago
Total assets stood at $187M at the end of Q3 FY2026, up 77.7% from a year earlier and down 1.9% from the prior quarter. Over 3 fiscal years it compounded at +155.5% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +77.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 99.59M USD
- Year-over-year change
- +90.8%
- 4-year CAGR
- +46.9%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 99.59M | +90.8% |
| FY2024 | 2024-06-30 | 52.21M | +1069.6% |
| FY2023 | 2023-06-30 | 4.46M | -25.3% |
| FY2022 | 2022-06-30 | 5.97M | -72.1% |
| FY2021 | 2021-06-30 | 21.38M | — |
Total Assets vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 total assets of $187M is the 7th highest of the 10 companies compared; the peer median is $263.14M.
- Its year-over-year change of +77.7% is the highest of 10, against a peer median of -11.3%.
- Over three fiscal years its annual growth of +155.5% compares with a peer median of -3.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Dec 2025 | $534.71M | -11.3% | -8.7% | |
| Mar 2026 | $527.07M | -29.4% | +6.3% | |
| Mar 2026 | $422.89M | +23.0% | -3.7% | |
| Mar 2026 | $271.86M | +27.8% | +24.8% | |
| Mar 2026 | $263.14M | -16.5% | +38.2% | |
| Mar 2026 | $213.35M | -21.3% | -14.4% | |
| Mar 2026 | $187M | +77.7% | +155.5% | |
| Mar 2026 | $109.53M | -2.0% | -3.1% | |
| Mar 2026 | $56.91M | -11.7% | -26.3% | |
| Mar 2026 | $15.76M | +65.4% | -2.8% | |
| Peer median (excluding BNTC) | $263.14M | -11.3% | -3.1% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.